Earnings Call Summary | Inovio Pharmaceuticals(INO.US) Q1 2024 Earnings Conference
Earnings Call Summary | Inovio Pharmaceuticals(INO.US) Q1 2024 Earnings Conference
The following is a summary of the Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript:
以下是Inovio Pharmaceuticals, Inc.(INO)2024年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Inovio Pharmaceuticals reported a decrease in operational spend from $44.1M in Q1 2023 to $31.5M in Q1 2024, a decrease of 29%.
The net loss for Q1 2024 is $30.5M ($1.31 loss per share), lower than the $40.6M loss ($1.89 loss per share) during the same period in 2023.
The company concluded Q1 2024 with $105.6M in cash, cash equivalents, and short-term investments.
Recently, the company raised approximately $33M through an offering of common stock and pre-funded warrants in April.
Inovio Pharmicals報告稱,運營支出從2023年第一季度的4,410萬美元下降到2024年第一季度的3150萬美元,下降了29%。
2024年第一季度的淨虧損爲3,050萬美元(每股虧損1.31美元),低於2023年同期的4,060萬美元的虧損(每股虧損1.89美元)。
該公司在2024年第一季度結束時獲得了1.056億美元的現金、現金等價物和短期投資。
最近,該公司在4月份通過發行普通股和預先融資認股權證籌集了約3300萬美元。
Business Progress:
業務進展:
The company confirms its plan to file its BLA for 3107 in the second half of this year.
In preparation for potential approval and commercialization of INO-3107, targeting recurrent respiratory papillomatosis.
The FDA has given approval for the company to proceed with the Phase 3 trial for INO-3112 in combination with LOQTORZI for throat cancer.
Plans for a Phase 2/3 study with INO-4201 as an Ebola vaccine booster are expected to be submitted in the current quarter.
Inovio Pharmaceuticals is continuing its advancement on the Phase 3 trial for INO-3112, and is also expanding its commercial activities post-fundraising.
該公司確認計劃在今年下半年提交3107份的BLA。
爲針對複發性呼吸道乳頭瘤病的 INO-3107 的潛在批准和商業化做準備。
美國食品藥品管理局已批准該公司繼續進行 INO-3112 與 LOQTORZI 聯合治療咽喉癌的 3 期試驗。
以 INO-4201 作爲埃博拉疫苗加強劑的 2/3 期研究計劃預計將在本季度提交。
Inovio Pharmicals繼續推進 INO-3112 三期試驗,並在籌款後擴大其商業活動。
More details: Inovio Pharmaceuticals IR
更多詳情: Inovio 製藥 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。